Hospital to monitor all patients digitally with the use of technology and biosensors...
FDA cleared, evidence-based AI and machine learning-based algorithm detects heart disease-associated ischemia...
Z-Span : Advancements and Clinical Benefits...
Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction...
Strategic Divestments and Portfolio Streamlining...
Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming....
Personalized mental health coaching based on mood identification available on CareOS operating system...
Cordella PA Sensor System's Pivotal Regulatory Step...
New pacemakers offer 40% more battery life, extend Medtronic legacy of pacing leadership...
Established in 2000, South Korea based Seegene Inc is a leader in molecular diagnostics and achieved remarkable financial success with over $1 billion in revenue and 65 per cent gross margins. With a mission for a disease-free world and proactive pandemic prevention, Seegene seamlessly integrates high multiplex diagnostic assays with automated testing systems. In an interaction with BioSpectrum & MedTech Spectrum, Dr Seong-Youl Kim, Seegene's Senior Vice President, shares insights on the company...
